NEW YORK (Reuters Health)—Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors is associated with a doubling of the risk of central nervous system demyelinating disease, researchers from Denmark report. “Based on the current evidence anti-TNF should be used cautiously in patients with an own or family history of demyelinating disease,” Dr. Nynne…
Search results for: network
Unwelcome News about Medicare’s Rising Drug Plan Costs
CHICAGO (Reuters)—Seniors have received some unpleasant news in their mailboxes in recent weeks: premiums for many Medicare prescription drug insurance plans will rise at double-digit rates next year. Premiums for the ten most popular Medicare Part D prescription drug plans (PDPs) will rise an average of 8 percent next year—the fastest clip in five years,…
Complex Patients More Likely to Switch from Medicare Advantage
NEW YORK (Reuters Health)—Medicare Advantage plans might not be meeting the needs of patients requiring the costliest and most complex levels of care, a new study suggests. Between 2010 and 2011, such patients were more likely to switch from Medicare Advantage plans to traditional Medicare, rather than vice versa, researchers found. The results suggest people…
Telehealth Visits May Be an Option After Surgery
(Reuters Health)—People may happily, and safely, forgo in-person doctors’ visits after surgery by opting instead for talking with their surgeons by phone or video, suggests a small study of U.S. veterans. Most patients preferred the virtual visits and the doctors didn’t miss any infections that popped up after surgery, the researchers report in JAMA Surgery….
ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
ATLANTA—The American College of Rheumatology (ACR) has released new recommendations for the treatment of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (SpA). The guideline was developed with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network. It summarizes recommendations for both pharmacologic and non-pharmacologic treatments, including rehabilitation, management of patients with…
U.S. Antitrust Lawmakers Express Concern About Insurance Mergers
WASHINGTON (Reuters)—Republican and Democratic lawmakers expressed concern about two multi-billion dollar insurance mergers on Tuesday, using a Senate hearing to take issue with the companies’ arguments that they face expanding competition from new rivals. Sen. Mike Lee (R-UT), who chairs the Senate Judiciary Committee’s antitrust subcommittee, said he was worried that consumers would be “locked…
How Medicare’s Chronic Care Management Payments Could Affect Primary Care
(Reuters Health)—Medicare’s new “chronic care management” (CCM) payment program could make it more financially feasible for physicians to deliver services between visits. Under the new program, Medicare could reimburse primary care practices about $40 month for such things as medication management and communication with other doctors for patients who have two or more chronic medical…
FDA’s ‘Breakthrough Drug’ Terminology Confuses the Public
NEW YORK (Reuters Health)—What the Food and Drug Administration calls a ‘breakthrough’ drug is often not the same as what a layperson would call a breakthrough, a new study shows. The FDA uses the term more often, and for smaller advances, than people use it colloquially, and this may lead patients to have unwarranted confidence…
Chronic Care Management Payments Can Increase Primary Care Revenues
NEW YORK (Reuters Health)—Medicare’s new chronic care management (CCM) payments could boost revenues for primary care practices, but many could experience net losses due to opportunity costs of face-to-face visit time, according to results from a modeling study. “The loss of revenue when MD’s did all the work themselves was somewhat surprising,” Dr. Sanjay Basu,…
POP1-Based Treatments May Reduce Inflammation
A recent study analyzed inflammasome response, finding the POP1 PYRIN domain protein acts to decrease excessive inflammatory responses and prevent systemic inflammation. Researchers ultimately developed a drug based on POP1 and found it reduced inflammation in mice…
- « Previous Page
- 1
- …
- 65
- 66
- 67
- 68
- 69
- …
- 96
- Next Page »